Drug discovery has become an integral and ongoing element of every pharmaceutical
company's business strategy. There are a number of new technologies that are
increasingly being used to enhance pharmaceutical R+D. These technologies include
bioanalytical instruments, genomics, pharmacogenomics, combinatorial chemistry,
biochip, proteomics, bioinformatics and high throughput screening (HTS). Use
of emerging technologies in drug discovery such as lab on a chip (LOC), nanotechnology
and RNA interference (RNAi) is increasing at a rapid pace given their ability
to expedite, and improve the efficiency of drug discovery processes and reducing
time-to-market.
As stated by the recent report published by Global Industry Analysts, Inc.,
drug discovery technologies market is dominated by the United States and Europe,
which together account for over 78% of the world market estimated in the year
2008. Worldwide Bioanalytical instruments market, the largest segment of the
drug discovery technologies market, is projected to rise by US$7827.9 million
over the period 2008 to 2012. Driven by aging population, rise in disease incidence,
and favorable governmental initiatives, market for Pharmacogenomics in Europe
is projected to reach US$2.6 billion by 2015. Pharmacogenomics testing helps
optimize drug therapy by enabling the study of gene interactions with drugs.
This thereby lowers the number of clinical trials and the cost and time pressures
involved therein.
Major pharmaceutical companies have been aggressively conducting internal
research and development programs to generate new marketable products, materials
and technologies. Although the number of new products emerging from R&D
each year is rising significantly, percentage of successful product commercialization
and launches averages to just 10-15% of drugs under research. Given the hefty
funds that need to be injected into clinical trials of new drugs, pharmaceutical
outsourcing is gaining preeminence in both the drug discovery and drug development
phases. Pharmaceutical companies are also forming collaborations with drug discovery
facilitators such as Contract Research Organizations (CRO), and university research
centers.
Key players in the global and regional Drug Discovery Technologies market include
Abbott Laboratories, Affymetrix, Agilent Technologies, Albany Molecular Research,
Amersham Biosciences, Applera Corporation, ArQule, AstraZeneca, BD Biosciences,
Bio-Rad Laboratories, BioSciences Group, Caliper Life Sciences, Capital GenomiX,
Caprion Proteomics, Charles River Laboratories International, ChemBridge Corporation,
deCODE Genetics, Evotec AG, Galapagos NV, Incyte Corporation, Infinity Pharmaceuticals
Inc, Invitrogen Corporation, Medarex, Merck & Co., Millennium Pharmaceuticals,
National Center for Drug Screening, PerkinElmer, Pharmacopeia Inc, Proteome
Systems, Quantum Pharmaceuticals, Shimadzu, Sigma-Aldrich, Tecan Group, Thallion
Pharmaceuticals Inc, and Tripos, among others.
The report, titled "Drug Discovery Technologies: A Global Strategic Business
Report" published by Global Industry Analysts, Inc., provides a comprehensive
review of market trends, industry overview, product overview, product introductions/innovations,
and recent industry activity. The report analyzes market data and analytics
in value sales for regions such as the United States, Canada, Japan, Europe,
and Rest of World. The study also analyzes the Drug Discovery Technologies market
by the following technologies - bioanalytical instruments, high throughput screening
(HTS), biochip market, proteomics, genomics market, bioinformatics, pharmacogenomics
market, and other drug discovery technologies.
For more details about this research report, please visit http://www.strategyr.com/Drug_Discovery_Technologies_Market_Report.asp